B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction

被引:30
作者
Chen, Ling [1 ,2 ]
Azuma, Takeshi [3 ]
Yu, Weiwei [2 ]
Zheng, Xu [2 ]
Luo, Liqun [1 ,2 ]
Chen, Lieping [1 ,2 ,3 ,4 ]
机构
[1] Fujian Med Univ, Inst Immunotherapy, Fuzhou 350122, Fujian, Peoples R China
[2] Sun Yat Sen Univ, Lab Immunotherapy, Guangzhou 510080, Guangdong, Peoples R China
[3] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21218 USA
[4] Yale Univ, Dept Immunobiol, New Haven, CT 06520 USA
基金
中国国家自然科学基金;
关键词
B7-H1; PD-1; dominant antigen; cytolytic T cells; subdominant antigen; TUMOR REJECTION ANTIGEN; ANTITUMOR IMMUNITY; HUMAN CANCER; B7; FAMILY; PD-1; INDUCTION; BLOCKADE; IMMUNODOMINANCE; IDENTIFICATION; RECEPTOR;
D O I
10.1073/pnas.1722043115
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Induced B7-H1 expression in the tumor microenvironment initiates adaptive resistance, which impairs immune functions and leads to tumor escape from immune destruction. Antibody blockade of the B7-H1/PD-1 interaction overcomes adaptive resistance, leading to regression of advanced human cancers and survival benefits in a significant fraction of patients. In addition to cancer cells, B7-H1 is expressed on dendritic cells (DCs), but its role in DC functions is less understood. DCs can present multiple antigens (Ags) to stimulate dominant or subdominant T cell responses. Here, we show that immunization with multiple tumor Ag-loaded DCs, in the absence of B7-H1, vastly enhances cytotoxic T lymphocyte (CTL) responses to dominant Ag. In sharp contrast, CTL responses to subdominant Ag were paradoxically suppressed, facilitating outgrowth of tumor variants carrying only subdominant Ag. Suppressed CTL responses to subdominant Ag are largely due to the loss of B7-H1-mediated protection of DCs from the lysis of CTL against dominant Ag. Therefore, B7-H1 expression on DCs may help maintain the diversity of CTL responses to multiple tumor Ags. Interestingly, a split immunization approach, which presents dominant and subdominant Ags with different DCs, promoted CTL responses to all Ags and prevented tumor escape in murine tumor models. These findings have implications for the design of future combination cancer immunotherapies.
引用
收藏
页码:3126 / 3131
页数:6
相关论文
共 35 条
[1]   B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells [J].
Azuma, Takeshi ;
Yao, Sheng ;
Zhu, Gefeng ;
Flies, Andrew S. ;
Flies, Sarah J. ;
Chen, Lieping .
BLOOD, 2008, 111 (07) :3635-3643
[2]   Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma [J].
Bloom, MB ;
PerryLalley, D ;
Robbins, PF ;
Li, Y ;
ElGamil, M ;
Rosenberg, SA ;
Yang, JC .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (03) :453-459
[3]   Coupling and uncoupling of tumor immunity and autoimmunity [J].
Bowne, WB ;
Srinivasan, R ;
Wolchok, JD ;
Hawkins, WG ;
Blachere, NE ;
Dyall, R ;
Lewis, JJ ;
Houghton, AN .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (11) :1717-1722
[4]   Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future [J].
Chen, Lieping ;
Han, Xue .
JOURNAL OF CLINICAL INVESTIGATION, 2015, 125 (09) :3384-3391
[5]   Molecular mechanisms of T cell co-stimulation and co-inhibition [J].
Chen, Lieping ;
Flies, Dallas B. .
NATURE REVIEWS IMMUNOLOGY, 2013, 13 (04) :227-242
[6]   Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity [J].
Chen, LP .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (05) :336-347
[7]   Human MHC class I transgenic mice deficient for H2 class I expression facilitate identification and characterization of new HLA class I-restricted viral T cell epitopes [J].
Cheuk, E ;
D'Souza, C ;
Hu, NJ ;
Liu, YA ;
Lang, HL ;
Chamberlain, JW .
JOURNAL OF IMMUNOLOGY, 2002, 169 (10) :5571-5580
[8]   Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity [J].
Curiel, TJ ;
Wei, S ;
Dong, HD ;
Alvarez, X ;
Cheng, P ;
Mottram, P ;
Krzysiek, R ;
Knutson, KL ;
Daniel, B ;
Zimmermann, MC ;
David, O ;
Burow, M ;
Gordon, A ;
Dhurandhar, N ;
Myers, L ;
Berggren, R ;
Hemminki, A ;
Alvarez, RD ;
Emilie, D ;
Curiel, DT ;
Chen, LP ;
Zou, WP .
NATURE MEDICINE, 2003, 9 (05) :562-567
[9]  
Dong HD, 1999, NAT MED, V5, P1365
[10]  
Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730